论文部分内容阅读
孕激素法抗剂米非司酮在临床的应用越来越广泛,但米非司酮对胚胎的安全性,特别是对早期胚胎的发育有无影响,需要深入的研究.近年来未见有关这方面的报道.本文通过妊娠早期应用米非司酮观察其对胚胎器官的发育有无影响进行探讨.选择的对象为自诉停经40～49天女性,随机分为两组,以服用米非司酮者为实验组,采用宫腔插管吸官术为对照组.临床用药米非司酮为上海华联制药公司生产,服药量为150mg.胚囊排出后,选用完整或无较大组织缺损的胚胎,根据各项发育指标,确定胚胎的受精龄.满足上述条件能确定受精龄的标本共获55例,其中实验组30例,对照组25例,标本固定后,经酒精逐级脱水、常规石蜡包埋,切片、脱蜡和HE染色,明胶
Progestogen therapy mifepristone is more and more widely used in clinical practice, but mifepristone has no effect on the safety of embryos, especially on the development of early embryos, which needs further study. This article reports the use of mifepristone in early pregnancy to observe the development of embryonic organs whether or not to explore the choice of the object for private prosecutors 40 to 49 days after menopause men were randomly divided into two groups to take mifeprist Ketone for the experimental group, the use of intrauterine intubation as the control group clinical application of mifepristone Shanghai Hualian Pharmaceutical Company, the dose of 150mg. After the embryo sac is discharged, the choice of complete or no major tissue defects Of embryos, according to the various developmental indicators to determine the fertilization age of embryos to meet the above conditions can determine the fertilization age of a total of 55 specimens, of which 30 cases in the experimental group, control group of 25 cases, after the specimen was fixed by the gradual dehydration of alcohol, Routine paraffin embedding, sectioning, dewaxing and HE staining, gelatin